New England Journal of Medicine Publishes MINDACT Trial Results Proving the Clinical Utility of MammaPrint® in Assisting Physicians to Identify Early-Stage Breast Cancer Patients who can Safely Forgo Chemotherapy

08-24-2016

46% of patients identified as high risk for recurrence according to clinical-pathological factors as described in the publication, and who therefore would be usual candidates for adjuvant chemotherapy, were reclassified as Low Risk by MammaPrint® and MINDACT shows could possibly … Continued

MINDACT in the News

05-25-2016

News, videos, social media and more about the recently released MINDACT phase III, prospective randomized trial results  The primary analysis from the MINDACT clinical trial was presented by Martine Piccart, MD, PhD at the American Association for Cancer Research (AACR) annual meeting … Continued